The Consensus Molecular Subtypes of Colorectal Cancer

  title={The Consensus Molecular Subtypes of Colorectal Cancer},
  author={Justin Guinney and Rodrigo Dienstmann and Xin Wang and Aur{\'e}lien de Reyni{\`e}s and Andreas Schlicker and Charlotte Soneson and Laetitia Marisa and Paul Roepman and Gift Nyamundanda and Paolo Angelino and Brian M. Bot and Jeffrey S. Morris and Iris Simon and Sarah Gerster and Evelyn Fessler and Felipe de Sousa e Melo and Edoardo Missiaglia and Hena Ramay and David Barras and Krisztian Homicsko and Dipen Maheshbhai Maru and Ganiraju C. Manyam and Bradley M. Broom and Val{\'e}rie Boige and Beatriz Perez-Villamil and Ted Laderas and Ram{\'o}n Salazar and Joe W. Gray and Douglas Hanahan and Josep Tabernero and René Bernards and Stephen H. Friend and Pierre Laurent-Puig and Jan Paul Medema and Anguraj Sadanandam and Lodewyk F. A. Wessels and Mauro Delorenzi and Scott Kopetz and Louis Vermeulen and Sabine Tejpar},
  journal={Nature medicine},
  pages={1350 - 1356}
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. [] Key Method To resolve inconsistencies among the reported gene expression–based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing…

Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications.

The colorectal cancer (CRC) Subtyping Consortium has unified six independent molecular classification systems into a single consensus system with four distinct groups, known as the Consensus Molecular Subtypes (CMS).

Refining colorectal cancer classification and clinical stratification through a single-cell atlas

A dichotomy in tumor microenvironments across CMS subgroups exists by which patients with high cancer-associated fibroblasts and C1Q+TAM content exhibit poor outcomes, providing a higher level of personalization and precision than would distinct subtypes.

Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models

Combined data indicate that molecular subtypes are faithfully modelled in CRC cell cultures and PDXs, representing tumour cell intrinsic and stable features.

Molecular subtypes of colorectal cancer – brief review

This mini review will give some information about the most frequent molecular genetics changes in colorectal cancer and its molecular classification in four CMS subtypes due to its morphology, gene expression profile, somatic mutations and microsatellite instability.

Investigation of colorectal cancer in accordance with consensus molecular subtype classification

Novel prognostic factors were identified, and the relationship between chemotherapeutic drug resistance and CMS has been fortified by the compilation of research; thus, indicating that this review provides advanced insight into clinical questions and treatment strategies for CRC.

Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach

Understanding CMS is a crucial step in personalized medicine, although prospective clinical trials selecting patients by CMS are required to pass proof-of-concept before becoming a routine clinical tool in oncology routine care.

A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype

It is shown that determining regulatory networks is a powerful strategy to define drivers of distinct cancer subtypes, which possess the ability to identify subtype affiliation and to shed light on biological behavior.

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2

  • K. ChangJ. Willis E. Vilar
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2018
A model of pathway activation associated with CMS classification in colorectal carcinogenesis is proposed and shed light on the transcriptional landscape of premalignant colonic polyps and may help guide the development of future biomarkers or preventive treatments for CRC.

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

This study shows that CMS-based transcriptomic ITH is frequent in CC and impacts its prognosis, and may correspond to distinct functional statuses of CC cells suggesting plasticity between CMS-related cell populations.



Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer

The proposed subtypes provide a novel perspective on the heterogeneity of CRC and should be further explored retrospectively on existing clinical trial datasets and, when sufficiently robust, be prospectively assessed for clinical relevance in terms of prognosis and treatment response predictive capacity.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

A new unsupervised, iterative approach to stratify CRC tumor samples into subtypes based on genome-wide mRNA expression data is applied, which captures important features of CRC, and offers valuable insight into functional differences between CRC subtypes.

A colorectal cancer classification system that associates cellular phenotype and responses to therapy

Three subtypes have markedly better disease-free survival (DFS) after surgical resection, suggesting these patients might be spared from the adverse effects of chemotherapy when they have localized disease.

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

This work demonstrates, using an unsupervised classification strategy involving over 1,100 individuals with colon cancer, that three main molecularly distinct subtypes can be recognized, and provides evidence that this subtype relates to sessile-serrated adenomas.

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition

In most colorectal cancer (CRC) patients, outcome cannot be predicted because tumors with similar clinicopathological features can have differences in disease progression and treatment response.

Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior

Novel molecular subtypes in colon cancer with distinctbiological and clinical behavior that are established from the initiation of the tumor are identified.

Proteogenomic characterization of human colon and rectal cancer

Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Subtypes of stage III colon cancer, based on detection of mutations in BRAF (V600E) or KRAS, and MMR status that show differences in clinical and pathologic features and disease-free survival are identified.

Comprehensive molecular characterization of gastric adenocarcinoma

A comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project is described and a molecular classification dividing gastric cancer into four subtypes is proposed.

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Based on gene expression patterns, gastric cancers are classified into 3 subtypes with differences in molecular and genetic features and response to therapy; this information might be used to select specific treatment approaches for patients with gastric cancer.